A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer-Reference-Cited by-同舟云学术

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

Published:2013-12 Issue:18 Volume:49 Page:3763-3772
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Martin Miguel,Bonneterre Jacques,Geyer Charles E.,Ito Yoshinori,Ro Jungsil,Lang Istvan,Kim Sung-Bae,Germa Caroline,Vermette Jennifer,Wang Kenneth,Wang Kongming,Awada Ahmad

Funder

Pfizer Inc.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Cancer statistics;Jemal;CA Cancer J Clin,2009

2. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy;Andreopoulou;J Clin Oncol,2008

3. Prognostic/predictive factors in breast cancer;Masood;Clin Lab Med,2005

4. Management of breast cancer in the genome era;Morrow;Annu Rev Med,2009

5. Extending survival with chemotherapy in metastatic breast cancer;O’Shaughnessy;Oncologist,2005

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis;Revista Peruana de Medicina Experimental y Salud Pública;2024-05-08

2. Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer;Cancer Control;2024-01

3. Efficacy of tyrosine kinase inhibitors examined by a combination of Raman micro-spectroscopy and a deep wavelet scattering-based multivariate analysis framework;The Analyst;2024

4. Novel HER-2 Targeted Therapies in Breast Cancer;Cancers;2023-12-23

5. Neratinib for HER2-positive breast cancer with an overlooked option;Molecular Medicine;2023-10-06